Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804980 · ClinicalTrials.gov registry record · Phase 4
Desifor-expand (mhif)
A Phase 4 study of Statin Adverse Reaction and Statin Therapy, sponsored by Minneapolis Heart Institute Foundation.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06804980: Recruiting Phase 4 study of Statin Adverse Reaction and Statin Therapy, sponsored by Minneapolis Heart Institute Foundation.
NCT06804980 is a Phase 4 study of Statin Adverse Reaction and Statin Therapy that is actively recruiting participants, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06804980, a Phase 4 study of Statin Adverse Reaction and Statin Therapy, is actively recruiting participants, sponsored by Minneapolis Heart Institute Foundation.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
Primary Outcome
To determine the prevalence of true statin intolerance, defined by a statistical difference in the mean musculoskeletal symptom score while on statin therapy compared to placebo, in patients previously identified as statin intolerant.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rosuvastatin (Crestor)
Study Locations (1)
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT06804980 shows while recruiting
NCT06804980 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Statin Adverse Reaction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06804980 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06804980 about?
NCT06804980 is a clinical study titled "Desifor-expand (mhif)". The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
What is the current status of trial NCT06804980?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06804980 study?
This clinical trial studies the following conditions: Statin Adverse Reaction, Statin Therapy, Statin.
What interventions are being tested in trial NCT06804980?
The interventions under investigation include: Placebo (DRUG), Rosuvastatin (Crestor) (DRUG).
Who is sponsoring clinical trial NCT06804980?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804980 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Statin Adverse Reaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06804980's enrollment target sits among peer trials
100 770th of 2000 higher than 1,149 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI